90Yttrium-labelled Anti-CD66 Monoclonal Antibody
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00637767)
Timeline
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 3Immunity, passive
CEACAM3 immunity, passive
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- y90 anti-cd66 monoclonal antibody bw 250/183
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04856215 | Phase 2 | Jun 30, 2021 | University of London |
| NCT04082286 | Phase 1 | May 31, 2016 | University of London |
| NCT00637767 | Phase 2 | Dec 1, 2007 | Moorgreen Hospital, Southampton |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of London | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1